Imvax
Imvax is a clinical-stage biotechnology company focused on the development of patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with unmet medical needs.
4
Funding Rounds
$192.4m
Money raised
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| Da*** An***** (e************ |
|
- | - |
| Ar**** W. Ho** |
|
- | - |
| D. Cr*** Ho**** | - | - | - |
| Pe*** Co** | - | - | - |
Funding
Funding series
Funding Series Analysis
The company Imvax has raised a total of $80m in funding over 4 rounds.
Key Insights:
- Imvax , September 2019: $40m
- Imvax Series B: $25m
- Imvax Series A: $15m
- Imvax, Inc. funding round, July 2020: $112.37m
Imvax , September 2019
$40m
Imvax Series B
$25m
Imvax Series A
$15m
Imvax, Inc. funding round, July 2020
$112.37m
Industries
Imvax is active in the following industries: